Spring Bank Pharmaceuticals, Inc. Appoints Scott Smith to its Board of Directors
August 16, 2018 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
Former Celgene President & COO Joins Spring Bank Board HOPKINTON, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical...
Spring Bank Announces Pricing of Public Offering of Common Stock
August 08, 2018 21:33 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass. and NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) today announced the pricing of an underwritten public offering of 3,000,000 shares...
Spring Bank Announces Proposed Public Offering of Common Stock
August 08, 2018 16:01 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass. and NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) today announced that it intends to offer and sell, subject to market conditions,...
Spring Bank Announces Positive Study Results from the Inarigivir ACHIEVE Trial
August 02, 2018 06:00 ET
|
Spring Bank Pharmaceuticals, Inc.
Maximum Reduction in HBV DNA up to 2.76log10 and HBV RNA up to 5.0log1028% of Inarigivir Treated Patients Demonstrate a HBsAg Response with a Mean Reduction of 0.8log10 and a Maximum Reduction of...
Spring Bank Pharmaceuticals Reports Second Quarter Financial Results
August 01, 2018 16:01 ET
|
Spring Bank Pharmaceuticals, Inc.
Conference Call Scheduled for Thursday, August 2 at 8:00 a.m. EDT to Provide Corporate Update HOPKINTON, Mass., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a...
Spring Bank to Present at Jefferies 2018 Global Healthcare Conference
May 29, 2018 08:30 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., May 29, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals Provides Corporate Update and Reports First Quarter Financial and Operational Results
April 27, 2018 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
Presented inarigivir 25 mg and 50mg cohorts from Phase 2 ACHIEVE trial in chronic hepatitis B patients at two scientific conferences Continues to advance SB 11285, a next-generation STING agonist,...
Spring Bank Announces Expanded Inarigivir Data from the ACHIEVE Trial to Be Presented at The International Liver Congress™
April 10, 2018 08:30 ET
|
Spring Bank Pharmaceuticals, Inc.
*Results from full 24 weeks of dosing from the first two cohorts of Part A in the ongoing Phase 2 ACHIEVE trial in hepatitis B to be highlighted in oral and poster presentations *30% of patients in...
Spring Bank Announces Presentation of Combined Inarigivir 25 mg and 50 mg 12 and 24 Week ACHIEVE Results Demonstrating Enhanced Anti-Viral Efficacy in HBeAg-Negative Patients
March 14, 2018 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
Data from the combined first two low dose inarigivir cohorts at weeks 12 and 24 with sequential Viread dosing demonstrate significant reductions in HBV DNA, HBV RNA and HBsAg Data to be presented at...
Spring Bank to Present at Cowen & Company 38th Annual Health Care Conference
March 09, 2018 14:19 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., March 09, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...